Quick View
| Metric | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥44.81B | ¥44.18B | +1.4% |
| Operating Income | ¥3.09B | ¥3.27B | −5.5% |
| Ordinary Income | ¥3.07B | ¥3.31B | −7.2% |
| Net Income | ¥1.86B | ¥2.08B | −10.8% |
| ROE | 4.7% | 5.1% | - |
Executive Summary
For the cumulative Q3 period of the fiscal year ending March 2026, revenue increased while profits declined. The key point is that, despite higher revenue, reduced cost absorption capacity put downward pressure on earnings. Revenue was ¥44.81B (+1.4% YoY), Operating Income was ¥3.09B (-5.5%), Ordinary Income was ¥3.07B (-7.2%), and Net Income was ¥1.86B (-10.8%). The core Medical Services business posted higher revenue but lower segment profit, weighing on consolidated profitability.
Factors Affecting Performance
【Revenue】Revenue increased 1.4% YoY to ¥44.81B. Medical Services, which accounted for approximately 67.2% of external revenue, led growth with revenue of ¥30.09B (+2.8%), while Interior Health declined 1.1% to ¥14.31B and other segments declined 5.8% to ¥0.41B. Overall revenue growth was supported by the expansion of the core business.
【Profit and Loss】Operating Income declined 5.5% to ¥3.09B, Ordinary Income declined 7.2% to ¥3.07B, and Net Income declined 10.8% to ¥1.86B. The gross margin of 56.1% was broadly in line with the previous year, but the SG&A ratio rose to 49.2%, causing the Operating Income margin to decline to 6.9% from approximately 7.4% in the previous year. By segment, the Medical Services profit margin declined by approximately 90bp from the previous year to 7.6%, and the resulting decline in profit despite higher revenue was the primary cause of lower earnings. The effective tax rate was high at approximately 39.0%, also limiting the conversion of pre-tax income into Net Income. Extraordinary losses of ¥0.03B, including business restructuring expenses, were immaterial, and the impact of temporary factors was limited. In conclusion, the Company recorded higher revenue but lower profits.
Segment Analysis
Medical Services reported revenue of ¥30.09B (+2.8% YoY), segment profit of ¥2.30B (-7.8%), and a profit margin of 7.6%, down from approximately 8.5% in the previous year, indicating deteriorating profitability despite higher revenue. Interior Health reported revenue of ¥14.31B (-1.1%), segment profit of ¥0.77B (-3.4%), and a profit margin of 5.4%, showing broadly flat profitability but lower revenue and profit. The other segments were immaterial in scale, with revenue of ¥0.41B and profit of ¥0.00B. Adjustments for corporate expenses and other items deteriorated from +¥0.011B in the previous year to -¥0.004B, slightly reducing consolidated profit. The recovery of profitability in Medical Services, which accounts for approximately 70% of consolidated revenue, will be the key to improving the consolidated profit margin going forward.
Key Financial Metrics
【Profitability】The Operating Income margin was 6.9%, down from approximately 7.4% in the same period of the previous year, while the Net Income margin also contracted to 4.1% from approximately 4.7%. The gross profit margin remained high at 56.1%, but the increase in the SG&A ratio to 49.2% was the primary cause of the deterioration in the Operating Income margin.【Cash Flow Quality】Net Income was ¥1.86B versus pre-tax income of ¥3.04B, resulting in a high effective tax rate of approximately 39.0%. Comprehensive Income was ¥1.55B, below Net Income of ¥1.86B, with a negative ¥0.35B remeasurement adjustment related to retirement benefits accounting for the difference.【Investment Efficiency】ROE was 4.7%, constrained by the low Net Income margin and total asset turnover. Total assets were ¥67.09B and net assets were ¥39.30B, both declining from the previous year.【Financial Soundness】The Equity Ratio improved to 58.6% from 57.2% in the previous year. In addition to cash and deposits of ¥6.87B, current assets substantially exceeded current liabilities. Interest-bearing debt was limited, indicating a stable financial foundation.
Cash Flow Analysis
Although detailed disclosure of the statement of cash flows is not available, changes in the balance sheet provide insight into cash movements. Cash and deposits declined to ¥6.87B from ¥7.22B in the previous year, while total current assets contracted to ¥35.19B from ¥38.48B. Total assets declined to ¥67.09B from ¥70.89B, indicating a trend toward contraction in the overall asset base. Meanwhile, the Equity Ratio improved to 58.6%, and the capital structure remained conservative, with total liabilities of ¥27.79B against net assets of ¥39.30B. Retained earnings increased to ¥35.91B from ¥35.42B in the previous year, indicating continued accumulation and maintenance of capital strength through retained earnings.
Quality of Earnings
Extraordinary income and losses were slightly negative relative to Ordinary Income of ¥3.07B, consisting of extraordinary losses of ¥0.03B, including ¥0.02B in business restructuring expenses. The impact on pre-tax income of ¥3.04B was immaterial as a temporary factor. Non-operating income was ¥0.14B and non-operating expenses were ¥0.16B, leaving non-operating income and expenses broadly balanced, with no significant factors indicating a material deviation from the recurring earnings structure. Comprehensive Income of ¥1.55B was below Net Income of ¥1.86B, primarily due to the negative ¥0.35B remeasurement adjustment related to retirement benefits. This is an accounting adjustment associated with changes in interest rates and the investment environment and does not directly represent the Company’s recurring earning power. The effective tax rate was high at approximately 39.0%, making the heavy tax burden an important consideration when assessing earnings quality.
Earnings Forecast and Guidance
The full-year Company plan calls for revenue of ¥61.50B (+1.5% YoY), Operating Income of ¥4.20B (-10.5%), and Ordinary Income of ¥4.20B (-10.3%), meaning that the Company’s own plan already factors in lower profits. The cumulative Q3 progress rates were 72.9% for revenue and 73.5% for Operating Income, while the progress rate for Ordinary Income was broadly at the same level, slightly below the standard 75% progress benchmark. To achieve the plan, Q4 revenue of ¥16.69B and Operating Income of ¥1.11B will be required. The required Operating Income margin is approximately 6.7%, slightly below the cumulative actual margin of 6.9%. While the earnings forecast was revised during the current quarter, there was no revision to the dividend forecast.
Shareholder Returns
The Q2 dividend was ¥17.00 per share, and the full-year dividend forecast is ¥41.00. Based on forecast EPS of ¥79.09, the forecast Payout Ratio is approximately 51.8%, which is within a sustainable range based on earnings. Deducting the interim dividend of ¥17.00 from the annual dividend of ¥41.00 implies a year-end dividend of ¥24.00. There was no revision to the dividend forecast during the current quarter, and no change in the policy regarding dividend increases or reductions was indicated. The financial foundation, consisting of net assets of ¥39.30B and retained earnings of ¥35.91B, provides support for continued dividend payments.
Risk Factors
-
Declining profitability in the core business: Medical Services accounts for approximately 67% of consolidated external revenue, but although revenue increased 2.8% YoY, segment profit declined 7.8% and the profit margin fell to 7.6%. The recovery of cost absorption capacity will be key to the consolidated profit margin.
-
Weak demand for Interior Health: Revenue declined 1.1% YoY and segment profit declined 3.4%, with lower revenue and profit continuing. A delay in the recovery of demand poses a risk to earnings.
-
Volatility related to retirement benefits: Other comprehensive income was negative ¥0.31B, primarily due to the negative ¥0.35B remeasurement adjustment related to retirement benefits. The impact on net assets from changes in interest rates and the investment environment should be closely monitored.
Industry Benchmark (For Reference; Compiled by the Company)
Industry Benchmark (manufacturing)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 6.9% | 8.6% (4.3%–12.7%) | −1.7pt |
| Net Income Margin | 4.1% | 6.4% (2.8%–10.3%) | −2.3pt |
The Company’s profitability was below the industry median, with both its Operating Income margin and Net Income margin ranking relatively low among its peers.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 1.4% | 3.3% (-2.1%–8.9%) | −1.9pt |
The revenue growth rate was also slightly below the industry median, with the pace of revenue growth relatively moderate compared with peers.
※Source: Compiled by the Company
Key Takeaways from the Financial Results
-
While revenue increased 1.4% YoY, Operating Income declined 5.5%, making the focus of the current period the recovery of profit margins rather than the growth rate.
-
The profit margin of Medical Services, which accounts for approximately 70% of consolidated revenue, declined by approximately 90bp from the previous year. Improving the profitability of this business will be a prerequisite for achieving the full-year plan.
-
The Equity Ratio improved to 58.6% from the previous year, indicating a stable financial foundation. However, ROE remained at 4.7%, and the progress rates for the full year were slightly below the standard benchmark, at 73.5% for Operating Income and 70.1% for Net Income.
Theoretical Share Price (Reference Value)
| Scenario | Theoretical Share Price |
|---|---|
| bear (bearish) | ¥1,074 |
| base (base case) | ¥1,090 |
| bull (bullish) | ¥1,109 |
| Calculation Assumption | Value |
|---|---|
| Book Value Per Share (BPS) | ¥1,178 |
| Adjusted Forecast EPS | ¥82.9 |
| Cost of Equity r | 9.77% (10-year government bond 2.77% + equity risk premium 6.00% + size premium 1.00%) |
| Residual Income Persistence Factor ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 51.8% |
| Forecast EPS Confidence Adjustment | ×1.049 (based on the actual guidance achievement rate of companies in the same industry) |
| Implied PBR / PER | 0.93x / 13.1x |
Sensitivity: ¥1,060–¥1,121 at ±1% for the cost of equity, and ¥1,087–¥1,092 at ±0.1 for ω.
Notes:
- Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
- Net assets as of the quarter-end are used; there is a timing difference relative to the full-year forecast.
(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)
This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 earnings were modestly weaker than the prior year, with revenue growth insufficient to offset higher operating costs. Revenue increased 1.4% YoY to ¥44.81bn. Gross profit rose 2.8% YoY to ¥25.13bn, exceeding the pace of revenue growth. Consequently, gross margin improved by 55bp YoY to 56.1%. SG&A expenses increased 3.7% YoY to ¥22.04bn, outpacing sales growth and absorbing the gross-profit improvement. Operating income declined 5.5% YoY to ¥3.09bn. Operating margin contracted by 51bp YoY to 6.9%. Ordinary income fell 7.2% YoY to ¥3.07bn, reflecting a modest deterioration in the non-operating balance. Net income declined 10.7% YoY to ¥1.86bn. Net margin fell by 57bp YoY to 4.1%. The effective tax rate was relatively high at 39.0%, with a tax burden ratio of 0.610. Comprehensive income decreased 33.3% YoY to ¥1.55bn, below reported net income due primarily to negative other comprehensive income. Medical Service remained the core business by segment profit contribution, although its profit declined more sharply than revenue. Interior Health revenue and profit both fell modestly, maintaining a lower margin than Medical Service. Financial liquidity remains strong, supported by a 264.0% current ratio, 216.7% quick ratio, and ¥13.87bn of cash plus short-term investment securities. Leverage is manageable, with 12.4% debt-to-capital and interest coverage of 58.23x. The principal operating issue is working-capital efficiency, as disclosed inventory-day measures of 128 days and 88 days both exceed applicable benchmarks and the cash conversion cycle is 149 days. Full-year guidance implies a substantial Q4 contribution, but Q3 cumulative progress is slightly below a standard 75% seasonal run rate. Management has revised its forecast, and the disclosed full-year outlook calls for revenue growth but lower operating and ordinary profit. Dividend coverage appears reasonable based on the forecast payout ratio, while the large YoY increase in treasury stock indicates material capital deployment through repurchases.
Profitability Analysis
The supplied annualized DuPont analysis shows ROE of 6.3%, composed of a 4.1% net profit margin, 0.891x asset turnover, and 1.71x financial leverage. ROE is below the 8% reference level, principally because the net margin remains modest rather than because of excessive financial leverage. Revenue grew 1.4% YoY, while gross profit increased 2.8%, lifting gross margin to 56.1% from 55.5% in the prior-year period. This 55bp gross-margin expansion demonstrates favorable gross-profit resilience. However, SG&A rose 3.7% YoY, well ahead of revenue growth, creating negative operating leverage. As a result, operating income decreased 5.5% YoY and operating margin compressed to 6.9% from 7.4%, a 51bp decline. Net margin similarly fell to 4.1% from 4.7%, a 57bp contraction. The decline in the net margin exceeded the operating-margin decline because ordinary income fell 7.2% and the effective tax rate was 39.0%. The five-factor analysis indicates that interest burden is strong at 0.987, so financing costs are not the main constraint on returns. Interest expense of ¥0.53bn was well covered by EBIT, as indicated by 58.23x interest coverage. The tax burden ratio of 0.610 is below a normal 0.70 reference point, indicating that tax expense materially limits conversion of pre-tax profit into net income. Medical Service generated segment profit of ¥2.30bn, down 7.8% YoY, on revenue growth of 2.8% to ¥30.09bn; its segment margin declined 87bp to 7.6%. Interior Health reported revenue of ¥14.31bn, down 1.1% YoY, and segment profit of ¥0.77bn, down 3.4% YoY; its segment margin was broadly stable at 5.4%. Medical Service is the core business, contributing roughly 75% of combined reportable-segment profit, but it also accounted for most of the segment-profit decline. The earnings profile remains operationally sound, but a return to profit growth requires SG&A discipline and restoration of Medical Service margin.
Growth Assessment
Growth was low quality at the consolidated profit level: revenue rose ¥0.63bn YoY, but operating income fell ¥0.18bn and net income fell ¥0.23bn. Medical Service was the principal sales-growth driver, adding ¥0.82bn of external revenue YoY. This growth was offset by a ¥0.16bn decline in Interior Health external revenue and a ¥0.03bn decline in Other revenue. The group’s gross-profit growth exceeded revenue growth, suggesting that pricing, product mix, or cost control supported gross profitability. Nevertheless, the increase in SG&A exceeded gross-profit growth in absolute terms, preventing revenue growth from translating into higher operating earnings. The full-year forecast is for revenue of ¥61.50bn, operating income of ¥4.20bn, ordinary income of ¥4.20bn, and net income attributable to owners of ¥2.65bn. Q3 cumulative revenue progress is 72.9% of the full-year forecast, 2.1 percentage points below the standard 75% Q3 run rate. Operating-income progress is 73.5%, 1.5 percentage points below the standard rate, while net-income progress is 70.1%, 4.9 percentage points below. Achieving guidance requires Q4 revenue of approximately ¥16.69bn, operating income of ¥1.11bn, and net income of ¥0.79bn. The implied Q4 operating margin is approximately 6.7%, broadly consistent with the Q3 cumulative 6.9% margin. Accordingly, the forecast appears to require execution consistent with the current margin profile rather than a sharp end-period recovery. The forecast calls for 1.5% revenue growth but a 10.5% decline in operating income, confirming management’s expectation of continued margin pressure for the full year.
Financial Health
Balance-sheet liquidity is robust. Current assets totaled ¥35.19bn against current liabilities of ¥13.33bn, producing a current ratio of 264.0% and working capital of ¥21.86bn. The quick ratio was also strong at 216.7%, indicating that liquidity does not depend on inventory liquidation. Cash and deposits were ¥6.87bn, and short-term investment securities were ¥7.00bn, together totaling ¥13.87bn. This liquid balance exceeds short-term loans of ¥1.54bn by 9.0x and supports the reported cash-to-short-term-debt ratio of 4.46x. Short-term debt represented 27.6% of interest-bearing debt, limiting immediate refinancing pressure. Debt-to-capital of 12.4% and the reported 0.71x debt-to-equity ratio indicate a manageable capital structure, well below the 2.0x aggressive-leverage warning level. Long-term loans were ¥4.03bn and bonds payable were ¥1.50bn; convertible bond-type bonds with subscription rights to shares were ¥5.03bn. Interest coverage of 58.23x provides a substantial cushion against interest-rate and refinancing risk. Total equity declined to ¥39.30bn from ¥40.61bn YoY despite retained earnings increasing to ¥35.91bn, reflecting capital returns and negative OCI effects. Treasury stock increased in magnitude from ¥0.21bn to ¥16.99bn, a ¥14.94bn movement that indicates substantial share repurchases or other treasury-share acquisition activity and reduces the equity buffer. Goodwill declined ¥1.76bn YoY, or 38.5%, to ¥2.81bn. The remaining goodwill exposure is limited at 0.7% of equity and 0.4% of assets, leaving the balance sheet minimally dependent on acquired intangible value. Property, plant and equipment totaled ¥20.83bn, or 31.0% of assets, consistent with a meaningful fixed-asset base. Asset retirement obligations totaled ¥3.43bn, equivalent to approximately 1.2% of total liabilities, a manageable level of site-restoration obligation.
Notable B/S Changes
Treasury stock: increased in magnitude by ¥14.94bn, from negative ¥0.21bn to negative ¥16.99bn (-728.8%) - indicates substantial share repurchases or treasury-share acquisition activity, reducing equity flexibility and making total capital returns more relevant than the dividend payout ratio alone. Goodwill: decreased by ¥1.76bn, from ¥4.57bn to ¥2.81bn (-38.5%) - lowers already limited M&A-related balance-sheet exposure; remaining goodwill equals only 0.7% of equity and 0.4% of total assets.
Cash Flow Quality
Dividend Sustainability
The Q2 dividend was ¥17.00 per share. Based on Q3 cumulative EPS of ¥55.44, the calculated interim-dividend payout ratio was 31.8%, indicating that the interim distribution was covered by reported earnings. The full-year dividend forecast is ¥41.00 per share against forecast EPS of ¥79.09, implying a dividend-only payout ratio of approximately 51.8%. This is below the 60% sustainability reference level and leaves a moderate earnings retention buffer. The forecast dividend implies a remaining year-end dividend of ¥24.00 per share after the ¥17.00 interim payment. Retained earnings of ¥359.13bn provide substantial accounting capacity for shareholder distributions. However, the ¥14.94bn YoY increase in treasury stock indicates significant capital deployment beyond dividends. Accordingly, shareholder-return analysis should distinguish the dividend payout ratio from the total return ratio, which would incorporate repurchases. Preserving earnings coverage is important given the current decline in operating and net profit and the elevated working-capital burden.
Risk Assessment
Business risks include Margin risk: SG&A increased 3.7% YoY versus revenue growth of 1.4%, causing a 51bp operating-margin contraction and negative operating leverage., Medical Service execution risk: the core segment’s profit declined 7.8% YoY despite 2.8% revenue growth, reducing its segment margin by 87bp to 7.6%., Inventory risk: the disclosed DIO alert of 128 days is above the 90-day warning level, signaling high inventory funding needs and potential product-mix, obsolescence, or stock-optimization risk., Inventory risk: a second disclosed DIO measure of 88 days exceeds the 60-day manufacturing efficiency benchmark, also indicating slower stock turnover than target., Working-capital risk: the disclosed 149-day cash conversion cycle exceeds the 120-day warning threshold, tying cash up in receivables and inventories for an extended period., Manufacturing and consumer-durables risk: demand volatility, raw-material and logistics cost inflation, product-quality exposure, and inventory aging can pressure gross margin and stock turnover..
Financial risks include Comprehensive income was ¥1.55bn, 16.7% below net income of ¥1.86bn, reflecting negative OCI and reducing the rate of equity accumulation., The 39.0% effective tax rate and 0.610 tax burden ratio restrained net-income conversion from pre-tax income., Treasury stock expanded by ¥14.94bn YoY, representing material capital allocation that reduces equity flexibility even though liquidity and interest coverage remain strong., Convertible bond-type bonds with subscription rights to shares of ¥5.03bn create potential dilution exposure alongside conventional borrowings..
Key concerns include The highest-priority issue is restoring SG&A efficiency so that gross-margin gains translate into operating-profit growth., The high-inventory-days alerts require attention because both disclosed measures are above their respective benchmarks and coincide with a 149-day cash conversion cycle., The full-year forecast requires a Q4 contribution that is broadly in line with the existing margin profile, but cumulative net-income progress is 4.9 percentage points below the standard Q3 pace., Capital returns should be monitored alongside earnings growth, particularly following the substantial increase in treasury stock..
Investment Implications
Key takeaways include Revenue expanded and gross margin improved, but SG&A growth exceeded sales growth and drove a 5.5% decline in operating income., The Medical Service segment remains the core earnings engine, but its margin deterioration is the most important segment-level earnings issue., Liquidity, debt service capacity, and goodwill exposure are favorable, limiting near-term balance-sheet stress., Working-capital efficiency is the principal operational balance-sheet concern, as reflected in DIO alerts of 128 days and 88 days and a 149-day cash conversion cycle., The full-year dividend forecast implies a manageable 51.8% dividend payout ratio, although total capital returns are elevated when treasury-share activity is considered..
Metrics to watch include Consolidated operating margin and SG&A growth relative to revenue growth, Medical Service revenue growth, segment profit, and segment margin, Inventory days under both disclosed calculation methodologies, Cash conversion cycle and the conversion of working capital into liquidity, Q4 revenue, operating income, and net income required to meet full-year guidance, Treasury-stock movements, share count, and the total return ratio, Effective tax rate and tax burden ratio.
Regarding relative positioning, The company combines a defensive liquidity profile, low goodwill dependence, and very strong interest coverage with sub-8% annualized ROE and a mid-single-digit operating-margin profile. Relative financial resilience is strong, but operational positioning is constrained by elevated inventory duration, a long cash conversion cycle, and current negative operating leverage.